In this edition:
Prognostic biomarkers for CAR T-cell therapy in MM
Biological determinants of PFS with cilta-cel in R/RMM
Role of MRD in RRMM with CAR T-cell/TCE therapy
Biomarkers for cytopenia with CAR T-cell therapy in RRMM
ZUMA-2 & ZUMA-18: brexu-cel for RRMCL
Brexu-cel in high-risk RRMCL
CD19 CAR T-cell therapy for Richter’s transformation
GPRC5D-targeted CAR T-cell therapy for RRMM
CD7-targeted CAR T-cell therapy in CD7-positive RRAML
Double-/triple-hit lymphoma in the CAR T-cell era
Please login below to download this issue (PDF)